Quantcast

Latest familial hypercholesterolemia Stories

2014-07-30 08:32:55

- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y., July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to...

2014-06-01 12:20:22

Data From Phase 3 TESLA Study in Patients With Homozygous Familial Hypercholesterolemia (HoFH) and Phase 2/3 TAUSSIG Study in Patients With Severe Familial Hypercholesterolemia Presented in Late-Breaking Session at EAS 2014 THOUSAND OAKS, Calif., June 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 TESLA study evaluating its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), in patients with homozygous...

2014-03-29 16:20:11

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C)...

2014-03-27 04:20:44

Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT PARIS and TARRYTOWN, N.Y., March 27, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from alirocumab clinical studies will be presented at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, D.C. March 29-31. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein...

2014-03-24 20:23:34

Five Phase 3 Studies With Evolocumab (AMG 145) to be Featured in Late-Breaking and Clinical Research Presentations - Data Form the Basis of Global Filing Plan THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density...

2014-03-17 08:30:17

Study Meets Primary Endpoint of LDL Cholesterol Reduction THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C). The percent reduction in LDL-C, or "bad" cholesterol, was clinically meaningful and statistically...

2014-01-30 16:26:43

RUTHERFORD-2 Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 30, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 (RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2) trial evaluating evolocumab in combination with statins and other lipid-lowering therapies in patients with heterozygous familial hypercholesterolemia (HeFH) met its co-primary...

2014-01-28 16:26:04

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week...

2014-01-23 08:31:51

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 GAUSS-2 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2) trial evaluating evolocumab in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related